Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Explainer: COVID-19 vaccine patents dominate global trade talks

05/04/2021 | 09:12pm EDT
FILE PHOTO: The word

BRUSSELS (Reuters) - World Trade Organization members will assess on Wednesday signs of progress in talks on a proposal by South Africa and India to waive patent rights on COVID-19 vaccines in order to boost supply to developing countries.

They want to ease rules of the WTO's Trade-Related Aspects of Intellectual Property (TRIPS) agreement. WTO decisions are based on consensus, so all 164 members need to agree.

Ten meetings in seven months have failed to produce a breakthrough, with 60 proposal sponsors from emerging economies, backed by a chorus of campaign groups, Nobel laureates and former world leaders, pitted against richer developed countries, such as Switzerland, the United States and in the European Union, where many pharmaceutical companies are based.

WHERE ARE THE TALKS NOW? After a 10th round of talks on April 30, the waiver proposal's backers said they would revise their text from October in time for the next TRIPS council meeting in the second half of May before a further discussion on June 8-9.

The new text could be more limited than the current proposal.

Norway's ambassador Dagfinn Sorli, the council chair who will brief Wednesday's WTO General Council, expressed "careful optimism".

World Health Organization chief Tedros Adhanom Ghebreyesus talked on Monday of "encouraging progress", but said the process needed to be completed as soon as possible. The WHO said in April that of 700 million vaccines globally administered, only 0.2% had been in low-income countries.


The Indian/South African proposal in October says property rights such as patents, industrial designs, copyright and protection of undisclosed information hinder timely access to affordable vaccines and medicines essential to combat COVID-19.

They say the waiver should last for an unspecified time period, with an annual review until it terminates, and call for unhindered global sharing of technology and know-how.

They say there cannot be a repeat of the early years of the HIV/AIDS pandemic, when a lack of access to life-saving medicines cost at least 11 million African lives.

The WHO head and 375 civil society and campaign groups such as Doctors Without Borders back the proposal and former leaders from Britain's Gordon Brown to Mikhail Gorbachev of the Soviet Union have jointly written to U.S. President Joe Biden urging him to support it.


Big drug companies oppose patent waivers, as do Britain, Switzerland and the United States. The main Western producers are Moderna, Johnson & Johnson, AstraZeneca and jointly Pfizer and BioNTech.

They say vaccine development is unpredictable and costly and that strong IP protection helped provide the incentive for the development of vaccines in record time and will do so again in work on tackling new variants or in a future pandemic.

Proponents counter that some of the money was public funds.

Big Pharma also says vaccine-making is difficult - witness the production problems non-specialist AstraZeneca has faced - so suspending patents alone will not bring more shots.

Complex vaccines require deep cooperation between developers and manufacturers. Any failure to make them properly could undermine public confidence in vaccine safety, they say.

They also point to over 260 partnership agreements already in place for production and distribution and comment that, under the existing TRIPS agreement, governments can allow produces to make a patented product without the consent of the patent owner. Developing countries have such "compulsory licences" to push down prices for HIV/AIDS medication from 2002 to 2007.

The situation though is fluid. In Brazil, the only developing country to oppose the waiver, the Senate has passed a bill to suspend COVID-19 vaccine patents. It has become quieter at the WTO since April.

The White House said last week it was considering options to maximise global supply of vaccines, including backing the waiver.


WTO director-general Ngozi Okonjo-Iweala has suggested a "third way" as a compromise, laying out global action to increase vaccine access after a meeting with producers, governments and others.

She urged vaccine makers to increase technology transfer to bring in new manufacturing capacity and to be transparent on contracts and pricing.

U.S. Trade Representative Katherine Tai told the same meeting that extraordinary times required courage and sacrifice from governments and leaders - but also from industry. On Tuesday, she said economic recovery depended on addressing global vaccine inequity.

(Reporting by Philip Blenkinsop; Editing by Angus MacSwan)

By Philip Blenkinsop

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.10% 7632 Delayed Quote.5.37%
MODERNA, INC. 0.01% 158.832 Delayed Quote.51.77%
All news about ASTRAZENECA PLC
02:57pASTRAZENECA  : Goldman Sachs maintains a Sell rating
02:46pASTRAZENECA  : Secures Shareholder Approval for Improved CEO Pay Package, But Ne..
02:24pASTRAZENECA  : Brazil recommends suspending use of Oxford Covid vaccine on pregn..
12:46pASTRAZENECA  : Mexico says U.S. to share AstraZeneca vaccine after testing
12:45pAstraZeneca runs into 'meaningful' investor revolt over pay
12:39pASTRAZENECA  : Slovakia suspends use of AstraZeneca COVID-19 vaccine as a recipi..
12:32pData on Covid-19 Vaccines for Children Under 12 Expected by Late Fall, Health..
12:14pASTRAZENECA  : Slovakia halts use of AstraZeneca coronavirus vaccine
11:18aASTRAZENECA  : The latest news on COVID-19 developments in Canada for Tuesday, M..
11:07aAlberta to stop giving first doses of AstraZeneca COVID-19 shot as supply dwi..
More news
Financials (USD)
Sales 2021 30 955 M - -
Net income 2021 4 540 M - -
Net Debt 2021 10 937 M - -
P/E ratio 2021 30,0x
Yield 2021 2,62%
Capitalization 142 B 142 B -
EV / Sales 2021 4,93x
EV / Sales 2022 4,39x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Average target price 130,30 $
Last Close Price 109,02 $
Spread / Highest target 52,2%
Spread / Average Target 19,5%
Spread / Lowest Target -11,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.19%448 388
ROCHE HOLDING AG-2.35%289 530
PFIZER, INC.7.53%222 346
ABBVIE INC.8.46%205 270
NOVARTIS AG-5.03%198 266